Multiple Sclerosis at the Limits 2018: Multimedia

Tuesday 6th & Wednesday 7th November 2018

The role of comorbidities in multiple sclerosis
Dr Ruth Ann Marrie
Departments of Internal Medicine and Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada

The potential role of statins in treatment of multiple sclerosis
Professor John Greenwood
Hugh Davson Professor of Biomedical Research and Head of the Department of Cell Biology, Institute of Ophthalmology, University College London, UK

Smoking and multiple sclerosis
Dr Anna Hedström
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

Exercise intervention in the management of MS
Professor Rob Motl
Professor and Director of Research, Department of Physical Therapy; Associate Director of Research, UAB|Lakeshore Collaborative; Associate Director, UAB Center for Exercise Medicine; Director, REACT Mobile Technology Laboratory; Co-Director, Exercise Neuroscience Research Laboratory, The University of Alabama at Birmingham, AL USA

Haemopoietic stem cell transplantation in the management of multiple sclerosis
Professor Richard K. Burt
Chief of Immunotherapy and Autoimmune Diseases & Professor of Medicine, Division of Immunotherapy, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Mesenchymal stem cell transplantation in MS
Professor Dimitrios Karussis
Director of the Hadassah Unit of Neuroimmunology and cell therapies, Department of Neurology and Agnes-Ginges Centre for Neurogenetics, Hadassah-Hebrew University Medical Organisation, Jerusalem, Israel

Are current patient expectations of cellular treatments realistic?
Professor Gianvito Martino
Scientific Director, San Raffaele Scientific Institute; Professor of Experimental Biology, Vita Salute San Raffaele University, Milan, Italy

Is B-cell depletion sufficient as a treatment strategy in MS?
Professor Fredrik Piehl
Professor of Clinical Neuroscience, Department of Clinical Neuroscience, The Karolinska Institutet, Stockholm, Sweden

Professor Gavin Giovannoni
Barts and The London School of Medicine and Dentistry, London, UK

Dr David Cottrell
Senior Clinical Lecturer in Neurology, University of Bristol, UK

Derisking lymphopenia in the management of MS
Professor Alasdair Coles
Professor of Neuroimmunology, Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK

Managing pharmacovigilance burden in MS
Associate Professor Stephen Reddel
Staff Specialist Neurologist, Concord Repatriation & General Hospital Sydney; Consultant Neurologist The Brain & Mind Centre, University of Sydney, Australia

PML and multiple sclerosis
Professor David Clifford
Professor of Neurology and Medicine & Melba and Forest Seay Professor of Clinical Neuropharmacology in Neurology, Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA

A practical guide to treatment cessation
Dr Robert Bermel
Staff Neurologist and Director, Mellen Center for Multiple Sclerosis; Neurological Institute, Cleveland Clinic

Hand function as an outcome measure in clinical trials
Professor Dr Bernard Uitdehaag
Professor of Neurology, Chair of the Department of Neurology, Director of the MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands

Designing disease modifying therapy trials in more advanced disease
Professor Gary Cutter
Professor of Biostatistics, University of Alabama at Birmingham, School of Public Health, Department of Biostatistics, Birmingham, AL, USA

Using MRI as an outcome measure in progressive MS
Dr Arman Eshaghi
Research Associate, Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK

The identification of potential treatment targets in advancing MS
Professor Bruno Stankoff
Professor of Neurology at Pierre and Marie Curie University, Paris, France